$2.49
+11.16%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$2.30
From 52W high−46.10%
Volume728572.00
Market cap$107.81M
P/E (TTM)—
P/S (TTM)31.8x
Div yield—
Key dataNov 4, 2026
Open
$2.30
From 52W high
−46.10%
Volume
728572.00
Market cap
$107.81M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−3.8x
P/E (TTM)
—
RSI (14)
38.0
MomentumView details →
1D Return
+11.16%
YTD Return
−12.73%
SummaryUpdated Jun 1, 2026
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) is a clinical-stage biopharmaceutical company founded in 2015 and headquartered in Wilmington, Delaware. The company went public in December 2017 and focuses on developing novel therapeutics for central nervous system disorders, particularly targeting the treatment of suicidal depression and bipolar depression. NRx has evolved from a pure research and development organization into a company pursuing a dual strategy of drug development and clinical service delivery through its subsidiary Hope Therapeutics.
Similar companies
Latest newsMore news →
The U.S. Food and Drug Administration approved NRx Pharmaceuticals' Abbreviated New Drug Application for Preservative-Free Ketamine.5d agoNRX Pharmaceuticals, Inc. announced that it will issue a press release before market open and host a conference call at 8:30 a.m. ET on October 30, 2026, to discuss a regulatory milestone for preservative-free ketamine.6d agoNRx Pharmaceuticals announced completion of three commercial-condition process-validation lots of preservative-free ketamine ahead of the November 10 GDUFA goal date.16d ago